Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice

Nature Biotechnology

Volumn 21, Issue 4, 2003, Pages 387-391

  Smallshaw, Joan E ^a   Ghetie, Victor ^a,b   Rizo, Jose ^b   Fulmer, John R ^a   Trahan, Linda L ^a   Ghetie, Maria Ana ^a,b   Vitetta, Ellen S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELLS; IMMUNOLOGY; PROTEINS;

IMMUNOTOXINS;

GENETIC ENGINEERING;

IMMUNOTOXIN; INTERLEUKIN 2; PROTEIN; RECOMBINANT PROTEIN; RICIN A; TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; ENDOTHELIUM CELL; EVALUATION; GENE MUTATION; GENE SEQUENCE; GENETIC ENGINEERING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN STRUCTURE; PULMONARY VASCULAR LEAK; SEQUENCE ANALYSIS; SYNDROME; TUMOR XENOGRAFT; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

AMINO ACID MOTIFS; ANIMALS; CAPILLARY LEAK SYNDROME; ENDOTHELIUM; GENETIC ENGINEERING; IMMUNOTOXINS; LETHAL DOSE 50; LUNG; LYMPHOMA; MICE; MICE, SCID; MUTAGENESIS, SITE-DIRECTED; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; RICIN;

ANIMALIA;

EID: 0037382907     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt800     Document Type: Article

References (35)

1. Farah, R.A., Clinchy, B., Herrera, L. & Vitetta, E.S. The development of monoclonal antibodies for the therapy of cancer. Crit. Rev. Eukaryotic Gene Expr. 8, 321-356 (1998).
2. Sausville, E.A. & Vitetta, E.S. Monoclonal Antibody-Based Therapy of Cancer (Marcel Dekker, Boston, 1997).
3. Frankel, A.E., Kreitman, R.J. & Sausville, E.A. Targeted toxins. Clin. Cancer Res. 6, 326-334 (2000).
4. Amlot, P.L. et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82, 2624-2633 (1993).
5. Vitetta, E.S. et al. A phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51, 4052-4058 (1991).
6. Stone, M.J. et al. A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88, 1188-1197 (1996).
7. Engert, A. et al. A Phase I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89, 403-410 (1997).
8. + B-cell lymphoma. Clin. Cancer Res. 6, 1302-1313 (2000).
9. Schnell, R. et al. A Phase I study with an anti-CD30 ricin A chain immunotoxin (Ki-4.dgA). Clin. Cancer Res. 8, 1779-1786 (2003).
10. Sausville, E.A. et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood 85, 3457-3465 (1995).
11. Rosenberg, S.A. et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889-897 (1987).
12. Schindler, J., Sausville, E., Messmann, R., Uhr, J.W. & Vitetta, E.S. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin. Cancer Res. 7, 255-258 (2001).
13. Senderowicz, A.M. et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann. Intern. Med. 126, 882-885 (1997).
14. Soler-Rodriguez, A.M., Ghetie, M.A., Oppenheimer-Marks, N., Uhr, J.W. & Vitetta, E.S. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res. 206, 227-234 (1993).
15. Baluna, R., Rizo, J., Gordon, B.E., Ghetie, V. & Vitetta, E.S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. USA 96, 3957-3962 (1999).
16. Coulson, B.S., Londrigan, S.L., & Lee, D.J. Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells. Proc. Natl. Acad. Sci. USA 94, 5389-5394 (1997).
17. Baluna, R. & Vitetta, E.S. An in vivo model to study immunotoxin-induced vascular leak in human tissue. J. Immunother. 22, 41-47 (1999).
18. Baluna, R., Coleman, E., Jones, C., Ghetie, V. & Vitetta, E.S. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp. Cell Res. 258, 417-424 (2000).
19. Press, O.W., Vitetta, E.S., Farr, A.G., Hansen, J.A. & Martin, P.J. Evaluation of ricin A-chain immunotoxins directed against human T cells. Cell. Immunol. 102, 10-20 (1986).
20. Shen, G.-L. et al. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int. J. Cancer 42, 792-797 (1988).
21. Ghetie, M.A. et al. Antitumor activity of Fab and IgG-anti-CD22 immunotoxins in disseminated human B lymphomas grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res. 51, 5876-5880 (1991).
22. Soler-Rodriguez, A.M., Uhr, J.W., Richardson, J. & Vitetta, E.S. The toxicity of chemically deglycosylated ricin A-chain in mice. Int. J. Immunopharm. 14, 281-291 (1992).
23. Rosenstein, M., Ettinghausen, S.E. & Rosenberg, S.A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J. Immunol. 137, 1735-1742 (1986).
24. Ghetie, M.-A., Tucker, K., Richardson, J., Uhr, J. & Vitetta, E.S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 80, 2315-2320 (1992).
25. Baluna, R., Ghetie, V., Oppenheimer-Marks, N. & Vitetta, E.S. Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells. Int. J. Immunopharm. 18, 355-361 (1996).
26. Yan, X. et al. Structure-based identification of a ricin inhibitor. J. Mol. Biol. 266, 1043-1049 (1997).
27. Simpson, J.C., Lord, J.M. & Roberts, L.M. Point mutations in the hydrophobic C-terminal region of ricin A chain indicate that Pro250 plays a key role in membrane translocation. Eur. J. Biochem. 232, 458-463 (1995).
28. O'Hare, M. et al. Expression of ricin A chain in Escherichia coli. FEBS Lett. 216, 73-78 (1987).
29. Sambrook, J., Maniatis, T. & Fritsch, E.F. Molecular Cloning: A Laboratory Manual edn. 2 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
30. Ghetie, V. et al. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. J. Immunol. Methods 142, 223-230 (1991).
31. Knowles, P.P. & Thorpe, P.E. Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B. Anal Biochem. 160, 440-443 (1987).
32. Fraker, P.J. & Speck, J.C.J. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril. Biochem. Biophys. Res. Commun. 80, 849-857 (1978).
33. Kalbfleisch, J.D. & Prentice, R.L. The Statistical Analysis of Failure Time Data (Wiley, New York, 1980).
34. Shah, S.A. et al. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res. 53, 1360-1367 (1993).
35. Shumaker, R.C. PKCALC: a basic interactive program for statistic and pharmacokinetic analysis of data. Drug Metab. Rev. 17, 331-348 (1986).